Economic Analyses of GERD

  • N. Vakil
  • N. Guda


Proton Pump Inhibitor Complete Symptom Relief Erosive GERD Proton Pump Inhib Demand Therapy 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. [1]
    Levin TR, Schmittdiel JA, Kunz K, Henning JM, Henke CJ, Colby CJ, Selby JV (1997) Costs of acid reflux disorders to a health maintenance organization. Am J Med 103: 520–528PubMedCrossRefGoogle Scholar
  2. [2]
    Lair TJ, Fu Q, Anderson DR, Crawley JA (1998) Utilisation and expenditures in the treatment of patients with gastroesophageal reflux disease. Dis Manage Health Outcome 4(6): 325–336CrossRefGoogle Scholar
  3. [3]
    Agreus L, Borgquist L (2002) The cost of gastrooesophageal reflux disease, dyspepsia and peptic ulcer disease in Sweden. Pharmacoeconomics 20(5): 347–355PubMedCrossRefGoogle Scholar
  4. [4]
    Schwenkglenks M, Marbet UA, Szucs TD (2004) Epidemiology and costs of gastroesophageal reflux disease in Switzerland: a population-based study. Soz Praventivmed 49(1): 51–61PubMedGoogle Scholar
  5. [5]
    Wahlqvist P et al (1999) Measuring lost productivity in patients with gastro-oesophageal reflux disease using a productivity questionnaire (WPAI-GORD). Medical Decision Making 19: 532–536Google Scholar
  6. [6]
    Dean BB, Crawley JA, Schmitt CM, Wong J, Ofman JJ (2003) The burden of illness of gastro-oesophageal reflux disease: impact on work productivity. Aliment Pharmacol Ther 17(10): 1309–1317PubMedCrossRefGoogle Scholar
  7. [7]
    Kleinman L, McIntosh E, Ryan M, Schmier J, Crawley J, Locke GR 3rd, De Lissovoy G (2002) Willingness to pay for complete symptom relief of gastroesophageal reflux disease. Arch Intern Med 162(12): 1361–1366PubMedCrossRefGoogle Scholar
  8. [8]
    Kartman B, Stålhammar NO, Johannesson M (1996) Valuation of health changes with the contingent valuation method: a test of scope and question order effects. Health Economics 5: 531–541PubMedCrossRefGoogle Scholar
  9. [9]
    Hillman AL, Bloom BS, Fendrick AM, Schwartz JS (1992) Cost and quality effects of alternative treatments for persistent GERD. Arch Int Med 152: 1467–1472CrossRefGoogle Scholar
  10. [10]
    Glise H (1995) Quality of life and cost of therapy in reflux disease. Scand J Gastroenterol 210(Suppl): 38–42Google Scholar
  11. [11]
    Bate CM et al (1997) Omeprazole is more effective than cimetidine for the relief of all grades of gastro-oesophageal reflux disease-associated heartburn, irrespective of the presence or absence of endoscopic oesophagitis. Aliment Pharmacol Ther 11: 755–763PubMedCrossRefGoogle Scholar
  12. [12]
    Bate CM, Richardson PDI (1994) Cost-effectiveness of omeprazole in the management of gastroesophageal reflux disease in clinical practice. Br J Med Econ 7:81–97Google Scholar
  13. [13]
    Bate CM, Richardson PDI (1992) Symptomatic assessment and cost effectiveness of treatment for reflux oesophagitis: comparisons of omeprazole and histamine H2-receptor antagonists. Br J Med Econ 2: 37–48Google Scholar
  14. [14]
    Bloom B et al (1995) Omeprazole or ranitidine plus metoclopramide for patients with severe erosive esophagitis: a cost-effectiveness analysis. Pharmacoeconomics 8(4): 343–349PubMedCrossRefGoogle Scholar
  15. [15]
    Lindberg G (1994) Omeprazole vs ranitidine in reflux oesophagitis. Pharmacoeconomics 5: 27–34Google Scholar
  16. [16]
    Ofman JJ et al (2000) Cost effectiveness of rabeprazole versus generic ranitidine for symptom resolution in patients with erosive esophagitis. Am J Managed Care 6(8): 905–916Google Scholar
  17. [17]
    Phillips C, Moore A (1997) Trial and error-an expensive luxury: economic analysis of effectiveness of proton pump inhibitors and histamine anatgonists in treating reflux disease. Br J Med Econ 11: 55–63Google Scholar
  18. [18]
    Goeree R, O’Brien B, Hunt R, Blackhouse G, Willan A, Watson J (1999) Economic evaluation of long term management strategies for erosive oesophagitis. Pharmacoeconomics 16: 679–697PubMedCrossRefGoogle Scholar
  19. [19]
    Wahlquist P (2000) In Finland, Sweden and the UK, esomeprazole is cost-effective compared with omeprazole for the acute treatment of patients with reflux esophagitis. Value in Health 3: 360Google Scholar
  20. [20]
    Zagari M, Villa KF, Freston JW (1995) Proton pump inhibitors versus H2 receptor antagonists for the treatment of erosive gastroesophageal reflux disease. A cost-comparative study. Am J Managed Care 1: 247–255Google Scholar
  21. [21]
    Sonnenberg A, Indaomi J, Becker L (1999) Economic analysis of step-wise treatment of gastro-esophageal reflux disease. Ailment Pharmacol Ther 13: 1003–1013CrossRefGoogle Scholar
  22. [22]
    Inadomi JM, Jamal R, Murata GH, Hoffman RM, Lavezo LA, Virgil JM, Swanson KM, Sonnenberg A (2001) Step-down management of gastro-esophageal reflux disease. Gastroenterology 121: 1095–1100PubMedCrossRefGoogle Scholar
  23. [23]
    Howden CW, Henning JM, Huang B, Lukasik N, Freston JW (2001) Management of heartburn in a large, randomized, community-based study: comparison of 4 therapeutic strategies. Am J Gastroenterol 96: 1704–1710PubMedCrossRefGoogle Scholar
  24. [24]
    Kaplan-Machitz B, Spiegler GE, Zodet MW, Revicki DA (2000) Effectiveness and costs of omeprazole vs ranitidine for treatment of symptomatic gastroesophageal reflux disease in primary clinics in West Virginia. Arch Fam Med 9: 624–630CrossRefGoogle Scholar
  25. [25]
    Crawley JA, Andersson T, Joshua-Gotlib S, Levine D (1999) Are patients carrying the burden of managed care cost control measures. Am J Gastroenterol 94: 2750Google Scholar
  26. [26]
    Hungin P, Rubin G, O’Flanagan H (1999) Long-term prescribing of proton pump inhibitors in general practice. Br J Gen Practice 49: 451–453Google Scholar
  27. [27]
    Bardhan KD, Muller-Lissner S, Bigard M, Bianchi Porro G, Ponce J, Hosie J, Scott M, Weir D, Gillon K, Peacock R, Fulton C (1999) Symptomatic gastroesophageal reflux disease: double blind controlled study of intermittent treatment with omeprazole or ranitidine. BMJ 318: 502–507PubMedGoogle Scholar
  28. [28]
    Stalhammer NO, Carlsson J, Peacock R, Muller-Lissner S, Bigard MA, Porro GB, Ponce J, Hosie J, Scott M, Weir D, Fulton C, Gillon K, Bardhan K (1999) Cost-effectiveness of Omeprazole and ranitidine in Intermittent treatment of symptomatic GERD. Pharmacocconomics 16: 485–497Google Scholar
  29. [29]
    Lind T, Havelund T, Lundell L, Glise H, Lauritsen K, Pederson S, Anker-Hansen, Stubberod A, Eriksson G, Carlsson R, Junghard O (1999) On demand therapy with omeprazole for the long-term management of patients with heartburn without esophagitis — a placebo-controlled randomized trial. Aliment Pharmacol Ther 13: 907–914PubMedCrossRefGoogle Scholar
  30. [30]
    Talley N, Lauritsen K, Tunturi-Hihnala H, Lind T, Moum B, Bang C et al (2001) Esomeprazole 20 mg maintains symptom control in endoscopy-negative GERD: a randomized placebo-controlled trial of on-demand therapy for 6 months. Aliment Pharmacol Ther 15: 347–354PubMedCrossRefGoogle Scholar
  31. [31]
    Meineche-Schmidt V, Juhl HH, Ostergaard JE, Luckow A, Hvenegaard A (2004) Costs and efficacy of three different esomeprazole treatment strategies for long-term management of gastro-oesophageal reflux symptoms in primary care. Aliment Pharmacol Ther 19(8): 907–915PubMedCrossRefGoogle Scholar
  32. [32]
    Viljakka M, Nevalainen J, Isolauri J (1997) Lifetime costs of surgical versus medical treatment of severe gastro-oesophageal reflux disease in Finland. Scand J Gastroenterol 32(8): 766–772PubMedGoogle Scholar
  33. [33]
    Van Den Boom G, Go PM, Hameeteman W, Dallemagne B, Ament AJ (1996) Cost effectiveness of medical versus surgical treatment in patients with severe or refractory gastroesophageal reflux disease in the Netherlands. Scand J Gastroenterol 31(1): 1–9Google Scholar
  34. [34]
    Heudebert GR, Marks R, Wilcox CM, Centor RM (1997) Choice of long-term strategy for the management of patients with severe esophagitis: a cost-utility analysis. Gastroenterology 112(4): 1078–1086PubMedCrossRefGoogle Scholar
  35. [35]
    Spechler SJ, Lee E, Ahnen D, Goyal RK, Hirano I, Ramirez F et al (2001) Long-term outcome of medical and surgical therapies for gastroesophageal reflux disease: follow-up of a randomized controlled trial. JAMA 285(18): 2331–2338PubMedCrossRefGoogle Scholar
  36. [36]
    Vakil N, Shaw M, Kirby R (2003) Clinical effectiveness of laparoscopic fundoplication in a U.S. community. Am J Med 114(1): 1–5PubMedCrossRefGoogle Scholar
  37. [37]
    Harewood GC, Gostout CJ (2003) Cost analysis of endoscopic antireflux procedures: endoluminal plication vs. radiofrequency coagulation vs. treatment with a proton pump inhibitor. Gastrointest Endosc 58(4): 493–499PubMedGoogle Scholar

Copyright information

© Springer-Verlag/Wien 2006

Authors and Affiliations

  • N. Vakil
    • 1
  • N. Guda
    • 1
  1. 1.University of Wisconsin Medical SchoolMilwaukeeUSA

Personalised recommendations